Recurrent mutations of RYR2 have been reported in several human carcinomas, including squamous cell carcinoma of the oral cavity [56] and lung [57], esophageal adenocarcinoma [58] and breast cancer [59]. Here, RYR2 is linked to breast carcinoma.